Direct comparison

GCP vs. GLP vs. GMP: Key Differences

GCP governs human trials, GLP governs nonclinical safety studies, GMP governs manufacturing. Compare the three ICH quality standards and when each applies.

Ask about GCP vs. GLP vs. GMP: Key Differences

Answers are drawn from this comparison and the rest of the CASRAI corpus, with a link to every source.

Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this

In summary

GLP, GCP, and GMP apply sequentially and in parallel across a product's lifecycle rather than being interchangeable versions of the same idea. GLP (21 CFR Part 58) governs the nonclinical laboratory safety studies — typically animal toxicology and pharmacology — that must exist before a sponsor can expose a human subject to an investigational product. GCP (ICH E6) governs the human clinical trial itself: informed consent, protocol adherence, investigator responsibilities, and data integrity. GMP (21 CFR Parts 210/211, and ICH Q7 for active pharmaceutical ingredients specifically) governs how the product being tested or sold is manufactured, tested, and released — a responsibility that runs continuously from the first investigational batch through commercial production, not just after approval. A single clinical trial routinely touches all three: the nonclinical package that justified starting it (GLP), the conduct of the trial itself (GCP), and the manufacturing of the drug product being administered (GMP).

Side-by-side comparison

Dimension	GCP	GLP	GMP
Full name	Good Clinical Practice	Good Laboratory Practice	Good Manufacturing Practice
What it governs	The design, conduct, recording, and reporting of trials involving human subjects	The conduct and reporting of nonclinical (animal and in vitro) safety studies	The manufacturing, testing, and release of the drug product or active pharmaceutical ingredient
Core governing standard	ICH E6 (current core revision: E6(R3), finalized January 2025)	21 CFR Part 58 in the US; OECD Principles of GLP internationally	21 CFR Parts 210 and 211 (drug cGMP) in the US; ICH Q7 specifically for active pharmaceutical ingredients
Subject of the activity	Human research participants	Animal models and in vitro/laboratory test systems	The drug product, biologic, or active pharmaceutical ingredient itself
Where it sits in development	Clinical phase — after nonclinical safety is established, through Phase 1–4	Nonclinical/preclinical phase — before first-in-human dosing, and for ongoing nonclinical safety work	Continuous — phase-appropriate GMP applies to investigational product manufacture from early clinical supply through commercial production
Primary purpose	Protect participant rights, safety, and well-being, and ensure trial data are credible	Ensure nonclinical safety data are complete, traceable, and reliable enough to support a decision to dose humans	Ensure the product administered or sold consistently meets its identity, strength, quality, and purity specifications
Core documentation	Protocol, informed consent forms, trial master file, monitoring visit reports	Study protocol, raw data, quality assurance unit inspection records, final study report	Batch production and control records, standard operating procedures, certificates of analysis
Who must comply	Sponsors, investigators, CROs, and IRBs/ethics committees	Nonclinical testing facilities and laboratories conducting regulated safety studies	Drug and API manufacturers, including contract manufacturing organizations
US regulatory oversight	FDA, primarily through the Bioresearch Monitoring (BIMO) inspection program	FDA, through GLP-specific facility inspections under Part 58	FDA CDER/CBER, through cGMP facility inspections; EMA and other authorities inspect in parallel for products marketed in their jurisdictions
Related ICH quality guidelines	ICH E8(R1) (general trial design considerations) is a frequent companion reference	Not part of the ICH Q-series; governed separately by national/OECD GLP principles	ICH Q7 (GMP for APIs), plus the broader ICH Q8–Q10 quality framework, including Q9 (Quality Risk Management) and Q10 (Pharmaceutical Quality System)

Common questions

FAQ

Can a single clinical trial be subject to all three standards at once?+

Yes, and in practice most are. The nonclinical toxicology package that justified starting the trial was generated under GLP, the trial itself is conducted under GCP, and the investigational product being administered to participants was manufactured under phase-appropriate GMP. A research administrator overseeing a trial is typically relying on all three, even though only GCP governs the clinical conduct directly.

Does GMP apply to investigational product, or only to a product that has already been approved?+

It applies to both, but not identically. Under 21 CFR 210.2(c), most Phase 1 investigational drugs are exempt from the full scope of 21 CFR Part 211, per FDA’s 2008 guidance on CGMP for Phase 1 investigational drugs — this is what "phase-appropriate GMP" means in practice. That exemption ends once a product enters Phase 2/3 or has already been used in a later-phase or marketed product, at which point full cGMP applies.

Is there a fourth standard that covers laboratory testing performed on clinical trial samples?+

Yes: Good Clinical Laboratory Practice (GCLP) is a hybrid standard applied to laboratories — such as central labs performing pharmacokinetic or biomarker analysis — that process specimens collected under a GCP-governed clinical trial. It combines GCP’s data-integrity and documentation expectations with GLP-style laboratory quality controls. See the GCLP dictionary entry for the full definition.

Which of the three is regulated by a single dedicated FDA rule?+

GLP and GMP each have a dedicated regulation (21 CFR Part 58 for GLP; 21 CFR Parts 210/211 for drug GMP). GCP does not have one equivalent standalone US regulation — it is implemented through a combination of regulations covering informed consent, IRB review, and IND conduct (21 CFR Parts 50, 56, and 312), harmonized internationally with ICH E6.

Going deeper